newsfilter
← Earnings
Earnings Releases·

Aligos Therapeutics — Third Quarter 2026 Earnings Summary

Aligos Therapeutics reported a net loss of $21.9 million for the third quarter of 2026, a decrease from the $31.5 million loss in the same period of 2025. The company's cash, cash equivalents, and investments totaled $31.1 million as of September 30, 2026, which is expected to fund operations into the first quarter of 2027. Recent business progress includes the completion of enrollment in the Phase 2 B-SUPREME study for pevifoscorvir sodium, with topline data anticipated in late 2027. Additionally, the partner Amoytop has advanced the ASO candidate ALG-170675 into Phase 1 clinical studies in China.

Company
ALIGOS THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology